HYDREIGHT TECHNOLOGIES INC (NURS.CA) Stock Fundamental Analysis
Canada - TSX-V:NURS - CA44877L1013 - Common Stock
4.93 CAD
+0.39 (+8.59%)
Overall NURS gets a fundamental rating of 5 out of 10. We evaluated NURS against 8 industry peers in the Health Care Technology industry. No worries on liquidiy or solvency for NURS as it has an excellent financial health rating, but there are worries on the profitability. NURS is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year NURS has reported negative net income.
In the past year NURS had a positive cash flow from operations.
1.2 Ratios
NURS's Return On Assets of 0.02% is fine compared to the rest of the industry. NURS outperforms 75.00% of its industry peers.
NURS has a Return On Equity of 0.04%. This is in the better half of the industry: NURS outperforms 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROIC | N/A |
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NURS's Profit Margin of 0.01% is fine compared to the rest of the industry. NURS outperforms 75.00% of its industry peers.
NURS has a Gross Margin (34.30%) which is comparable to the rest of the industry.
NURS's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 0.01% | ||
| GM | 34.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
2. Health
2.1 Basic Checks
NURS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NURS has been increased compared to 1 year ago.
There is no outstanding debt for NURS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
NURS has an Altman-Z score of 27.86. This indicates that NURS is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 27.86, NURS is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
NURS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 27.86 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
A Current Ratio of 1.49 indicates that NURS should not have too much problems paying its short term obligations.
With a decent Current ratio value of 1.49, NURS is doing good in the industry, outperforming 62.50% of the companies in the same industry.
NURS has a Quick Ratio of 1.49. This is a normal value and indicates that NURS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.49, NURS is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.49 | ||
| Quick Ratio | 1.49 |
3. Growth
3.1 Past
NURS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 99.54%, which is quite impressive.
Looking at the last year, NURS shows a very strong growth in Revenue. The Revenue has grown by 32.60%.
The Revenue has been growing by 137.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)99.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%257.14%
Revenue 1Y (TTM)32.6%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%79.24%
3.2 Future
The Earnings Per Share is expected to grow by 279.00% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 131.82% on average over the next years. This is a very strong growth
EPS Next Y974.04%
EPS Next 2Y440.3%
EPS Next 3Y279.01%
EPS Next 5YN/A
Revenue Next Year274.18%
Revenue Next 2Y194.65%
Revenue Next 3Y131.82%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Forward Earnings ratio of 17.43, the valuation of NURS can be described as rather expensive.
Based on the Price/Forward Earnings ratio, NURS is valued cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.35. NURS is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 17.43 |
4.2 Price Multiples
75.00% of the companies in the same industry are more expensive than NURS, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 2119.66 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as NURS's earnings are expected to grow with 279.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y440.3%
EPS Next 3Y279.01%
5. Dividend
5.1 Amount
No dividends for NURS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:NURS (11/5/2025, 7:00:00 PM)
4.93
+0.39 (+8.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners0.28%
Inst Owner ChangeN/A
Ins Owners2.14%
Ins Owner ChangeN/A
Market Cap232.70M
Revenue(TTM)18.48M
Net Income(TTM)1.50K
Analysts80
Price Target8.67 (75.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-12.58%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 17.43 | ||
| P/S | 12.59 | ||
| P/FCF | N/A | ||
| P/OCF | 204.39 | ||
| P/B | 68.17 | ||
| P/tB | 162.16 | ||
| EV/EBITDA | 2119.66 |
EPS(TTM)0
EYN/A
EPS(NY)0.28
Fwd EY5.74%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.02
OCFY0.49%
SpS0.39
BVpS0.07
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 0.01% | ||
| GM | 34.3% | ||
| FCFM | N/A |
ROA(3y)-98.35%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.69%
GM growth 5YN/A
F-Score6
Asset Turnover2.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 575.04% | ||
| Cap/Sales | 7.68% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1065.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.49 | ||
| Quick Ratio | 1.49 | ||
| Altman-Z | 27.86 |
F-Score6
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)341%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%257.14%
EPS Next Y974.04%
EPS Next 2Y440.3%
EPS Next 3Y279.01%
EPS Next 5YN/A
Revenue 1Y (TTM)32.6%
Revenue growth 3Y137.35%
Revenue growth 5YN/A
Sales Q2Q%79.24%
Revenue Next Year274.18%
Revenue Next 2Y194.65%
Revenue Next 3Y131.82%
Revenue Next 5YN/A
EBIT growth 1Y92.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1245.74%
EBIT Next 3Y347.79%
EBIT Next 5YN/A
FCF growth 1Y17.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y384.63%
OCF growth 3YN/A
OCF growth 5YN/A
HYDREIGHT TECHNOLOGIES INC / NURS.CA FAQ
Can you provide the ChartMill fundamental rating for HYDREIGHT TECHNOLOGIES INC?
ChartMill assigns a fundamental rating of 5 / 10 to NURS.CA.
What is the valuation status for NURS stock?
ChartMill assigns a valuation rating of 4 / 10 to HYDREIGHT TECHNOLOGIES INC (NURS.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for HYDREIGHT TECHNOLOGIES INC?
HYDREIGHT TECHNOLOGIES INC (NURS.CA) has a profitability rating of 2 / 10.
Can you provide the financial health for NURS stock?
The financial health rating of HYDREIGHT TECHNOLOGIES INC (NURS.CA) is 7 / 10.
What is the expected EPS growth for HYDREIGHT TECHNOLOGIES INC (NURS.CA) stock?
The Earnings per Share (EPS) of HYDREIGHT TECHNOLOGIES INC (NURS.CA) is expected to grow by 974.04% in the next year.